Skip to content

Radioembolization with Intra-arterial Angiotensin II to improve Tumor-absorbed dose: The RADIANT study

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-521870-33-00
Enrollment
15
Registered
2025-08-04
Start date
2026-01-05
Completion date
Unknown
Last updated
2025-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver cancer (primary or secondary)

Brief summary

TNR improvement factor: the TNR after AT-II infusion with subsequent direct 90Y microsphere injection as measured on 90Y PET/CT divided by the TNR after 99mTc-MAA without AT-II infusion as measured on SPECT/CT.

Detailed description

Toxicity profile of combining 90Y radioembolization with AT-II infusion (graded according to CTCAE v5.0), Technical success of AT-II infusion. Technical success is defined as the successful intra-arterial administration of AT-II (10 μg/min for 100 seconds) followed by immediate 90Y glass microsphere injection.

Interventions

Sponsors

Universitair Medisch Centrum Utrecht
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
TNR improvement factor: the TNR after AT-II infusion with subsequent direct 90Y microsphere injection as measured on 90Y PET/CT divided by the TNR after 99mTc-MAA without AT-II infusion as measured on SPECT/CT.

Secondary

MeasureTime frame
Toxicity profile of combining 90Y radioembolization with AT-II infusion (graded according to CTCAE v5.0), Technical success of AT-II infusion. Technical success is defined as the successful intra-arterial administration of AT-II (10 μg/min for 100 seconds) followed by immediate 90Y glass microsphere injection.

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026